Leerink Partners analyst David Risinger has maintained their bullish stance on PCVX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors, including Vaxcyte’s promising updates on their VAX-31 vaccine development. The company has taken strategic steps to enhance the potential success of their VAX-31 Phase 2 infant trials by incorporating a new optimized dose. This adjustment is expected to improve efficacy, although it will extend the trial completion timeline to the first half of 2027.
Additionally, Vaxcyte’s communication with the FDA regarding the VAX-31 adult development has been favorable, supporting their plans for a Phase 3 trial. Despite some delays in the projected timelines for both infant and adult trials, the company maintains a strong financial position with substantial cash reserves expected to sustain operations through mid-2028. These factors contribute to Risinger’s confidence in the company’s future prospects, justifying the Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $50.00 price target.
PCVX’s price has also changed dramatically for the past six months – from $87.420 to $30.010, which is a -65.67% drop .